1
|
Gutiérrez-García G, Martínez C, Boumendil A, Finel H, Malladi R, Afanasyev B, Tsoulkani A, Wilson KMO, Bloor A, Nikoloudis M, Richardson D, López-Corral L, Castagna L, Cornelissen J, Giltat A, Collin M, Fanin R, Bonifazi F, Robinson S, Montoto S, Peggs KS, Sureda A. Long-term outcome of patients receiving haematopoietic allogeneic stem cell transplantation as first transplant for high-risk Hodgkin lymphoma: a retrospective analysis from the Lymphoma Working Party-EBMT. Br J Haematol 2021; 196:1018-1030. [PMID: 34750806 DOI: 10.1111/bjh.17939] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2021] [Revised: 10/19/2021] [Accepted: 10/20/2021] [Indexed: 11/30/2022]
Abstract
We analysed long-term outcome of patients receiving haematopoietic allogeneic stem cell transplantation (allo-HSCT) as a first transplant for high-risk Hodgkin lymphoma (HL). One hundred and ninety patients were included in this study, 63% of them had previously received brentuximab vedotin and/or checkpoint inhibitors. Seventy patients (37%) received an unrelated donor allo-HSCT, 99 (51%) had myeloablative conditioning (MAC) and 60% had in vivo T-cell/depleted grafts (TCD). The 100-day cumulative incidence (CI) of grade II-IV acute graft-versus-host disease (GVHD) was 25% and the 3-year CI of chronic GVHD was 38%. The 3-year CI of non-relapse mortality (NRM) and relapse rate were 21% and 38% respectively. After a median follow-up of 58 months, 3-year overall survival (OS) and progression-free survival (PFS) were 58% and 41% respectively. Multivariate analysis showed that, in comparison to reduced-intensity conditioning regimens with or without TCD, MAC using TCD had similar NRM and a lower risk of relapse leading to significantly better OS and PFS. MAC without TCD was associated with higher NRM and worse survival outcomes. These results suggest that in patients with high-risk HL and candidates of allo-HSCT, a MAC strategy with TCD might be the best option.
Collapse
Affiliation(s)
- G Gutiérrez-García
- Department of Haematology, Bone Marrow Transplantation Unit, Hospital Clinic of Barcelona, University of Barcelona, Institut de Recerca Biomèdica August Pi i Sunyer, Barcelona, Spain
| | - C Martínez
- Department of Haematology, Bone Marrow Transplantation Unit, Hospital Clinic of Barcelona, University of Barcelona, Institut de Recerca Biomèdica August Pi i Sunyer, Barcelona, Spain
| | | | - H Finel
- Lymphoma Working Party, EBMT, Paris, France
| | - R Malladi
- School of Cancer Sciences, University of Birmingham, Centre for Clinical Haematology, Queen Elizabeth NHS Foundation Trust, Birmingham, UK
| | - B Afanasyev
- State Medical Pavlov University, St. Petersburg, Russia
| | | | | | - A Bloor
- Haematology and Transplant Unit, Christie Hospital NHS Foundation Trust and University of Manchester, Manchester, UK
| | - M Nikoloudis
- Haematology Department Heart of England NHS Trust, Birmingham, UK
| | - D Richardson
- Department of Haematology, Southampton General Hospital, Southampton, UK
| | | | - L Castagna
- Department of Haematology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
| | - J Cornelissen
- Erasmus MC Cancer Institute University Medical Centre Rotterdam Department of Haematology, Rotterdam, Netherlands
| | - A Giltat
- Department of Haematology, Medical University Hospital, Angers, France
| | | | - R Fanin
- Department of Haematology and Cellular Therapy 'Carlo Melzi', S. Maria della Misericordia University Hospital, DAME, University of Udine, Udine, Italy
| | - F Bonifazi
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, University of Bologna, Bologna, Italy
| | - S Robinson
- Department of Haematology and Oncology, Bristol University Hospital, Bristol, UK
| | - S Montoto
- St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK
| | - K S Peggs
- Department of Haematology, University College London Cancer Institute, London, UK
| | - A Sureda
- Clinical Department of Haematology, Institut Català d'Oncologia-Hospitalet, IDIBELL, University of Barcelona, Barcelona, Spain
| |
Collapse
|
2
|
Dreger P, Ngoya M, Litovich C, Finel H, Herrera AF, Sauter C, Kharfan‐Dabaja M, Sureda A, Blaise D, Castagna L, Corradini P, Pastano R, Arat M, Boumendil A, Dietrich S, Schmitz N, Glass B, Montoto S, Hamadani M. ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PERIPHERAL T‐CELL LYMPHOMA: COMPARABLE OUTCOMES OF HAPLO‐IDENTICAL VS. MATCHED DONORS. A CIBMTR & EBMT ANALYSIS. Hematol Oncol 2021. [DOI: 10.1002/hon.53_2879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- P. Dreger
- EBMT Lymphoma Working Party Paris France
| | - M. Ngoya
- EBMT Lymphoma Working Party Paris France
| | - C. Litovich
- CIBMTR Lymphoma Working Committee Milwaukee Wisconsin USA
| | - H. Finel
- EBMT Lymphoma Working Party Paris France
| | - A. F Herrera
- CIBMTR Lymphoma Working Committee Milwaukee Wisconsin USA
| | - C. Sauter
- CIBMTR Lymphoma Working Committee Milwaukee Wisconsin USA
| | | | - A. Sureda
- EBMT Lymphoma Working Party Paris France
| | - D. Blaise
- EBMT Lymphoma Working Party Paris France
| | | | | | - R. Pastano
- EBMT Lymphoma Working Party Paris France
| | - M. Arat
- EBMT Lymphoma Working Party Paris France
| | | | | | - N. Schmitz
- EBMT Lymphoma Working Party Paris France
| | - B. Glass
- EBMT Lymphoma Working Party Paris France
| | - S. Montoto
- EBMT Lymphoma Working Party Paris France
| | - M. Hamadani
- CIBMTR Lymphoma Working Committee Milwaukee Wisconsin USA
| |
Collapse
|
3
|
Burney C, Robinson S, Boumendil A, Finel H, Khvedelidze I, Hunter H, Poire X, Lioure B, Peggs K, Foa R, Pillai S, van Meerten T, Bargay Lleonart J, Schmid C, Vergote V, Ganser A, Castagna L, Mufti G, Montoto S. THE EFFICACY OF IBRUTINIB IN PATIENTS WITH RELAPSED MANTLE CELL LYMPHOMA AFTER FIRST LINE INTENSIVE CHEMO-IMMUNOTHERAPY AND ASCT - A RETROSPECTIVE STUDY FROM THE LWP-EBMT. Hematol Oncol 2019. [DOI: 10.1002/hon.53_2630] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- C.N. Burney
- Department of Haematology; University Hospitals Bristol NHS Trust; Bristol United Kingdom
| | - S. Robinson
- Department of Haematology; University Hospitals Bristol NHS Trust; Bristol United Kingdom
| | - A. Boumendil
- Lymphoma Working Party; European Society for Blood and Marrow Transplantation; Paris France
| | - H. Finel
- Lymphoma Working Party; European Society for Blood and Marrow Transplantation; Paris France
| | - I. Khvedelidze
- Lymphoma Working Party; European Society for Blood and Marrow Transplantation; Paris France
| | - H. Hunter
- Department of Haematology; University Hospitals Plymouth NHS Trust; Plymouth United Kingdom
| | - X. Poire
- Section of Haematology; Cliniques Universitaires St-Luc; Brussels Belgium
| | - B. Lioure
- Onco-Hematologie; Nouvel Hopital Civil; Strasbourg France
| | - K. Peggs
- Department of Haematology; University College London Hospitals NHS Trust; London United Kingdom
| | - R. Foa
- Division of Haematology; Univ. La Sapienza; Rome Italy
| | - S. Pillai
- Department of Haematology; University Hospital of North Staffordshire; Stoke-On-Trent United Kingdom
| | - T. van Meerten
- Hematologie Groningen; University Medical Center; Groningen Netherlands
| | - J. Bargay Lleonart
- Department of haematology; Hospital son Llatzer; Palma de Mallorca Spain
| | - C. Schmid
- Department of oncology and hematology; Klinikum Augsburg; Augsburg Germany
| | - V. Vergote
- Department of haematologie; University Hospital Gasthuisberg; Leuven Belgium
| | - A. Ganser
- Department of Hematology; Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School; Hannover Germany
| | - L. Castagna
- Bone Marrow Transplant Unit; Istituto Clinico Humanitas; Rozzano Milan Italy
| | - G. Mufti
- Department of Haematological Medicine; GKT School of Medicine; London United Kingdom
| | - S. Montoto
- Centre for Haemato-Oncology; Barts NHS Health Trust; London United Kingdom
| |
Collapse
|
4
|
Castagna L, Bramanti S, Devillier R, Pagliardini T, Sarina B, Lemarie C, Furst S, Mariotti J, Granata A, de Philippis C, Harbi S, Legrand F, Maisano V, Bouabdallah R, Carlo-Stella C, Calmels B, Chabannon C, Blaise D, Santoro A. IMPACT OF CLASS II HLA MISMATCH ON CLINICAL OUTCOMES IN HODGKIN LYMPHOMA PATIENTS RECEIVING HAPLOIDENTICAL STEM CELL TRANSPLANTATION (HAPLO-SCT) WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY). Hematol Oncol 2019. [DOI: 10.1002/hon.109_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- L. Castagna
- Hematology; Humanitas Research Center; Rozzano Italy
| | - S. Bramanti
- Hematology; Humanitas Research Center; Rozzano Italy
| | - R. Devillier
- Hematology; Institut Paoli Calmettes; Marseille France
| | | | - B. Sarina
- Hematology; Humanitas Research Center; Rozzano Italy
| | - C. Lemarie
- Hematology; Institut Paoli Calmettes; Marseille France
| | - S. Furst
- Hematology; Institut Paoli Calmettes; Marseille France
| | - J. Mariotti
- Hematology; Humanitas Research Center; Rozzano Italy
| | - A. Granata
- Hematology; Institut Paoli Calmettes; Marseille France
| | | | - S. Harbi
- Hematology; Institut Paoli Calmettes; Marseille France
| | - F. Legrand
- Hematology; Institut Paoli Calmettes; Marseille France
| | - V. Maisano
- Hematology; Institut Paoli Calmettes; Marseille France
| | | | | | - B. Calmels
- Hematology; Institut Paoli Calmettes; Marseille France
| | - C. Chabannon
- Hematology; Institut Paoli Calmettes; Marseille France
| | - D. Blaise
- Hematology; Institut Paoli Calmettes; Marseille France
| | - A. Santoro
- Hematology; Humanitas Research Center; Rozzano Italy
| |
Collapse
|
5
|
Bazarbachi A, Boumendil A, Finel H, Castagna L, Dominietto A, Blaise D, Diez-Martin J, Tischer J, Gülbas Z, Labussière Wallet H, Lopez Corral L, Mohty M, Koc Y, Yakoub-Agha I, Schmid C, el Cheikh J, Arat M, Forcade E, Dreger P, Rocha V, Gutiérrez García G, Chalandon Y, Ferra C, Orvain C, Robinson S, Montoto S, Sureda A. HOW TO SELECT DONOR, STEM CELL SOURCE, AND CONDITIONING REGIMEN FOR HAPLOIDENTICAL TRANSPLANTS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR LYMPHOMA: A REPORT OF THE EBMT LWP. Hematol Oncol 2019. [DOI: 10.1002/hon.108_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- A. Bazarbachi
- Internal medicine American University of Beirut Medical Center Beirut, Lebanon
| | - A. Boumendil
- Lymphoma Working Party EBMT LWP Paris Office/Hôpital Saint-Antoine Paris; France
| | - H. Finel
- Lymphoma Working Party EBMT LWP Paris Office/Hôpital Saint-Antoine Paris; France
| | - L. Castagna
- Hematology Istituto Clinico Humanitas Rozzano Milano, Italy
| | - A. Dominietto
- Hematology Second Division of Hematology and Bone Marrow Transplantation, IRCCS AOU San Martino-IST Genoa, Italy
| | - D. Blaise
- Hematology Institut Paoli Calmettes Marseille, France
| | | | - J. Tischer
- Hematology Klinikum Grosshadern Munich, Germany
| | - Z. Gülbas
- Hematology Anadolu Medical Center Hospital Kocaeli, Turkey
| | | | | | - M. Mohty
- Hematology Hôpital Saint Antoine Paris, France
| | - Y. Koc
- Hematology Medical Park Hospitals Antalya, Turkey
| | | | - C. Schmid
- Hematology Klinikum Augsburg Augsburg, Germany
| | - J. el Cheikh
- Internal medicine American University of Beirut Medical Center Beirut, Lebanon
| | - M. Arat
- Hematology Florence Nightingale Sisli HospitalIstanbul, Turkey
| | | | - P. Dreger
- Hematology University of Heidelberg Heidelberg, Germany
| | - V. Rocha
- Hematology Hospital Sirio-Libanes Sao Paulo, Brazil
| | - G. Gutiérrez García
- Hematology Hospital Clinic, Universitat de Barcelona IDIBAPS, Barcelona, Spain
| | - Y. Chalandon
- Hematology Hôpitaux Universitaires Geneva, Switzerland
| | - C. Ferra
- Hematology ICO-Hospital Universitari Germans Trias i Pujol Barcelona, Spain
| | | | - S. Robinson
- Hematology Bristol Oncology Centre Bristol, United Kingdom
| | - S. Montoto
- Hematology Barts Health NHS TrustLondon, United kingdom
| | - A. Sureda
- Hematology ICO - Hospital Duran i Reynals Barcelona, Spain
| |
Collapse
|
6
|
de Philippis C, Legrande F, Bramanti S, Montes de Oca C, Dulery R, Bouabdallah R, Granada A, Devillier R, Mariotti J, Sarina B, Harbi S, Maisano V, Furst S, Pagliardini T, Weiller P, Lemarie C, Calmels B, Chabannon C, Carlo-Stella C, Santoro A, Mohty M, Blaise D, Castagna L. CHECKPOINT INHIBITION BEFORE HAPLOIDENTICAL TRANSPLANTATION IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA PATIENTS IS ASSOCIATED WITH HIGHER PFS WITHOUT INCREASED TOXICITIES. Hematol Oncol 2019. [DOI: 10.1002/hon.107_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
| | - F. Legrande
- Hematology; Institut Paoli Calmettes; Marseille France
| | - S. Bramanti
- Hematology; Humanitas Cancer Center; Rozzano Italy
| | | | - R. Dulery
- Hematology; Hospital Saint-Antoine; Paris France
| | | | - A. Granada
- Hematology; Institut Paoli Calmettes; Marseille France
| | - R. Devillier
- Hematology; Institut Paoli Calmettes; Marseille France
| | - J. Mariotti
- Hematology; Humanitas Cancer Center; Rozzano Italy
| | - B. Sarina
- Hematology; Humanitas Cancer Center; Rozzano Italy
| | - S. Harbi
- Hematology; Institut Paoli Calmettes; Marseille France
| | - V. Maisano
- Hematology; Institut Paoli Calmettes; Marseille France
| | - S. Furst
- Hematology; Institut Paoli Calmettes; Marseille France
| | | | - P.J. Weiller
- Hematology; Institut Paoli Calmettes; Marseille France
| | - C. Lemarie
- Hematology; Institut Paoli Calmettes; Marseille France
| | - B. Calmels
- Hematology; Institut Paoli Calmettes; Marseille France
| | - C. Chabannon
- Hematology; Institut Paoli Calmettes; Marseille France
| | | | - A. Santoro
- Hematology; Humanitas Cancer Center; Rozzano Italy
| | - M. Mohty
- Hematology; Hospital Saint-Antoine; Paris France
| | - D. Blaise
- Hematology; Institut Paoli Calmettes; Marseille France
| | - L. Castagna
- Hematology; Humanitas Cancer Center; Rozzano Italy
| |
Collapse
|
7
|
Castagna L, Boubdallah R, Furst S, Coso D, El Cheikh J, Faucher C, Crocchiolo R, Granata A, Chabannon C, Lemarié C, Calmels B, Boher JM, Mohty M, Blaise D. Correction: Corrigendum: Disease status is a more reliable predictive factor than histology in lymphoma patients after reduced-intensity conditioning regimen and allo-SCT. Bone Marrow Transplant 2018; 53:234. [DOI: 10.1038/bmt.2018.1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
8
|
Bazarbachi A, Boumendil A, Finel H, Mohty M, Castagna L, Blaise D, Peggs K, Afanasyev B, Diez-Martin J, Corradini P, Socié G, Robinson S, Gutiérrez-García G, Bonifazi F, Yakoub-Agha I, Gülbas Z, Bloor A, Delage J, Esquirol A, Malladi R, Scheid C, Ghesquières H, Montoto S, Dreger P, Sureda A. BRENTUXIMAB VEDOTIN FOR RELAPSED HODGKIN LYMPHOMA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: a RETROSPECTIVE STUDY OF THE EBMT LYMPHOMA WORKING PARTY. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_71] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- A. Bazarbachi
- Department of internal medicine; American University of Beirut; Beirut Lebanon
| | - A. Boumendil
- EBMT LWP Paris Office; Hôpital Saint-Antoine; Paris France
| | - H. Finel
- EBMT LWP Paris Office; Hôpital Saint-Antoine; Paris France
| | - M. Mohty
- Service d'Hématologie et Thérapie Cellulaire; Hôpital Saint Antoine; Paris France
| | - L. Castagna
- Department of Hematology; Istituto Clinico Humanitas; Milan Italy
| | - D. Blaise
- Department of internal medicine; Institut Paoli Calmettes; Marseille France
| | - K. Peggs
- Department of internal medicine; University College London Hospital; London UK
| | - B. Afanasyev
- Department of internal medicine; First State Pavlov Medical University of St. Petersburg; St. Petersburg Russian Federation
| | - J. Diez-Martin
- Department of internal medicine; Hospital Gregorio Marañón; Madrid Spain
| | - P. Corradini
- IRCCS Istituto Nazionale dei Tumori; University of Milano; Milan Italy
| | - G. Socié
- Department of internal medicine; Hopital St. Louis; Paris France
| | - S. Robinson
- Department of internal medicine; University Hospital Bristol; Bristol UK
| | | | - F. Bonifazi
- S.Orsola-Malpighi Hospital; Bologna University; Bologna Italy
| | | | - Z. Gülbas
- Department of internal medicine; Anadolu Medical Center Hospital; Kocaeli Turkey
| | - A. Bloor
- Department of internal medicine; Christie NHS Trust Hospital; Manchester UK
| | - J. Delage
- Department of internal medicine; CHU Lapeyronie; Montpellier France
| | - A. Esquirol
- Department of internal medicine; Hospital Santa Creu i Sant Pau; Barcelona Spain
| | - R. Malladi
- Department of internal medicine; Queen Elizabeth Hospital; Birmingham UK
| | - C. Scheid
- Department of internal medicine; University of Cologne; Cologne Germany
| | - H. Ghesquières
- Department of internal medicine; Centre Hospitalier Lyon Sud; Lyon France
| | - S. Montoto
- Department of Haemato-oncology; St Bartholomew's Hospital; London UK
| | - P. Dreger
- Dept Medicine V; University of Heidelberg; Heidelberg Germany
| | - A. Sureda
- Department of Haematology; Institut Catala d'Oncologia, Hospital Duran I Reynals; Barcelona Spain
| |
Collapse
|
9
|
Legrand F, Le Floch AC, Granata A, Fürst S, Faucher C, Lemarie C, Harbi S, Bramanti S, Calmels B, El-Cheikh J, Chabannon C, Weiller PJ, Vey N, Castagna L, Blaise D, Devillier R. Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML. Bone Marrow Transplant 2016; 52:620-621. [PMID: 27941765 DOI: 10.1038/bmt.2016.326] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- F Legrand
- Department of Hematology, Institut Paoli-Calmettes, Marseille, France
| | - A-C Le Floch
- Department of Hematology, Institut Paoli-Calmettes, Marseille, France
| | - A Granata
- Department of Hematology, Institut Paoli-Calmettes, Marseille, France
| | - S Fürst
- Department of Hematology, Institut Paoli-Calmettes, Marseille, France
| | - C Faucher
- Department of Hematology, Institut Paoli-Calmettes, Marseille, France
| | - C Lemarie
- Cell therapy facility, Institut Paoli-Calmettes, Marseille, France.,CIC biothérapies: Inserm CBT-1409, Marseille, France
| | - S Harbi
- Department of Hematology, Institut Paoli-Calmettes, Marseille, France
| | - S Bramanti
- Departement of Hematology, Humanitas Cancer Center, Rozzano, Italy
| | - B Calmels
- Cell therapy facility, Institut Paoli-Calmettes, Marseille, France.,CIC biothérapies: Inserm CBT-1409, Marseille, France.,Centre de Recherche en Cancérologie de Marseille, Inserm, U1068, Institut Paoli-Calmettes, Marseille, France
| | - J El-Cheikh
- Department of Hematology, Institut Paoli-Calmettes, Marseille, France.,Bone marrow transplantation program, American University of Beirut, Beirut, Lebanon
| | - C Chabannon
- Cell therapy facility, Institut Paoli-Calmettes, Marseille, France.,CIC biothérapies: Inserm CBT-1409, Marseille, France.,Centre de Recherche en Cancérologie de Marseille, Inserm, U1068, Institut Paoli-Calmettes, Marseille, France.,Aix-Marseille Université UM 105, Marseille, France
| | - P-J Weiller
- Department of Hematology, Institut Paoli-Calmettes, Marseille, France.,Aix-Marseille Université UM 105, Marseille, France
| | - N Vey
- Department of Hematology, Institut Paoli-Calmettes, Marseille, France.,Centre de Recherche en Cancérologie de Marseille, Inserm, U1068, Institut Paoli-Calmettes, Marseille, France.,Aix-Marseille Université UM 105, Marseille, France.,CNRS UMR 7258, Marseille, France
| | - L Castagna
- Bone marrow transplantation program, American University of Beirut, Beirut, Lebanon
| | - D Blaise
- Department of Hematology, Institut Paoli-Calmettes, Marseille, France.,Centre de Recherche en Cancérologie de Marseille, Inserm, U1068, Institut Paoli-Calmettes, Marseille, France.,Aix-Marseille Université UM 105, Marseille, France.,CNRS UMR 7258, Marseille, France
| | - R Devillier
- Department of Hematology, Institut Paoli-Calmettes, Marseille, France.,Centre de Recherche en Cancérologie de Marseille, Inserm, U1068, Institut Paoli-Calmettes, Marseille, France.,Aix-Marseille Université UM 105, Marseille, France.,CNRS UMR 7258, Marseille, France
| |
Collapse
|
10
|
Genadieva-Stavrik S, Boumendil A, Dreger P, Peggs K, Briones J, Corradini P, Bacigalupo A, Socié G, Bonifazi F, Finel H, Velardi A, Potter M, Bruno B, Castagna L, Malladi R, Russell N, Sureda A. Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Ann Oncol 2016; 27:2251-2257. [DOI: 10.1093/annonc/mdw421] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2016] [Revised: 08/16/2016] [Accepted: 08/29/2016] [Indexed: 11/14/2022] Open
|
11
|
Castagna L, Sarina B, Crocchiolo R, Bramanti S, Furst S, Devillier R, Coso D, Bouabdallah R, Mokart D, Morabito L, Harbi S, Giordano L, Rimondo A, Jean Weiller P, Carlo-Stella C, Santoro A, Chabannon C, Blaise D. Outcomes of Hodgkin lymphoma patients who relapse after allogeneic stem cell transplantation. Bone Marrow Transplant 2016; 51:1644-1646. [PMID: 27748737 DOI: 10.1038/bmt.2016.257] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- L Castagna
- Hematology Department, Transplantation Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - B Sarina
- Hematology Department, Transplantation Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - R Crocchiolo
- Hematology Department, Transplantation Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - S Bramanti
- Hematology Department, Transplantation Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - S Furst
- Hematology Department, Transplantation Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - R Devillier
- Hematology Department, Transplantation Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - D Coso
- Hematology Department, Lymphoma Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - R Bouabdallah
- Hematology Department, Lymphoma Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - D Mokart
- Intensive Care Unit, Institut Paoli Calmettes, Marseille, France
| | - L Morabito
- Hematology Department, Transplantation Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - S Harbi
- Hematology Department, Transplantation Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - L Giordano
- Biostatistical Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - A Rimondo
- Hematology Department, Transplantation Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - P Jean Weiller
- Hematology Department, Transplantation Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - C Carlo-Stella
- Hematology Department, Transplantation Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy.,Department of Medical Biotechnology and Translational Medicine, University of Milano, Milano, Italy
| | - A Santoro
- Hematology Department, Transplantation Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy.,Humanitas University, Rozzano, Italy
| | - C Chabannon
- Cell Therapy Unit, Institut Paoli Calmettes, Marseille, France.,Aix-Marseille Université, Marseille, France.,Centre de Recherche en Cancérologie de Marseille, Inserm, Institut Paoli-Calmettes, Aix-Marseille Université, Marseille, France
| | - D Blaise
- Hematology Department, Transplantation Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy.,Hematology Department, Lymphoma Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy.,Aix-Marseille Université, Marseille, France.,Centre de Recherche en Cancérologie de Marseille, Inserm, Institut Paoli-Calmettes, Aix-Marseille Université, Marseille, France
| |
Collapse
|
12
|
O'Donnell PV, Eapen M, Horowitz MM, Logan BR, DiGilio A, Brunstein C, Fuchs EJ, Flowers MED, Salit R, Raj K, Pagliuca A, Bradstock K, Granata A, Castagna L, Furst S, Blaise D. Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from haploidentical donors after non-ablative conditioning: a matched-pair analysis. Bone Marrow Transplant 2016; 51:1599-1601. [PMID: 27526284 DOI: 10.1038/bmt.2016.215] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- P V O'Donnell
- Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.,Massachusetts General Hospital Cancer Center, Boston, MA, USA
| | - M Eapen
- Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA
| | - M M Horowitz
- Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA
| | - B R Logan
- Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA
| | - A DiGilio
- Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA
| | - C Brunstein
- Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA
| | - E J Fuchs
- Sydney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA
| | - M E D Flowers
- Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - R Salit
- Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - K Raj
- Guy's and St. Thomas' Hospitals NHS Hospitals Foundation Trusts, London, UK.,Department of Haematological Medicine, King's College Hospital, London, UK
| | - A Pagliuca
- Department of Haematological Medicine, King's College Hospital, London, UK
| | - K Bradstock
- Department of Hematology, Westmead Hospital, Westmead, New South Wales, Australia
| | - A Granata
- Department of Hematology, Institut Paoli Calmettes (IPC), Aix Marseille University (AMU), UM105, Centre de Reserche en Cancerologie (CRCM), Inserm U1068, CNRS UMR7258, Marseille, France
| | - L Castagna
- Department of Hematology, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Italy
| | - S Furst
- Department of Hematology, Institut Paoli Calmettes (IPC), Aix Marseille University (AMU), UM105, Centre de Reserche en Cancerologie (CRCM), Inserm U1068, CNRS UMR7258, Marseille, France
| | - D Blaise
- Department of Hematology, Institut Paoli Calmettes (IPC), Aix Marseille University (AMU), UM105, Centre de Reserche en Cancerologie (CRCM), Inserm U1068, CNRS UMR7258, Marseille, France
| |
Collapse
|
13
|
Locatelli SL, Careddu G, Inghirami G, Castagna L, Sportelli P, Santoro A, Carlo-Stella C. The novel PI3K-δ inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest. Leukemia 2016; 30:2402-2405. [PMID: 27499137 DOI: 10.1038/leu.2016.224] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Affiliation(s)
- S L Locatelli
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - G Careddu
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - G Inghirami
- Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY, USA.,Department of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Torino, Italy.,Department of Pathology, and NYU Cancer Center, New York University School of Medicine, New York, NY, USA
| | - L Castagna
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | | | - A Santoro
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy.,Humanitas University, Rozzano, Italy
| | - C Carlo-Stella
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy.,Department of Medical Biotechnology and Translational Medicine, University of Milano, Milano, Italy
| |
Collapse
|
14
|
Robinson SP, Boumendil A, Finel H, Schouten H, Ehninger G, Maertens J, Crawley C, Rambaldi A, Russell N, Anders W, Blaise D, Yakoub-Agha I, Ganser A, Castagna L, Volin L, Cahn JY, Montoto S, Dreger P. Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long-term disease control: an analysis from the Lymphoma Working Party of the EBMT†. Ann Oncol 2016; 27:1088-1094. [PMID: 26961149 DOI: 10.1093/annonc/mdw124] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2015] [Revised: 02/17/2016] [Accepted: 02/22/2016] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Patients with follicular lymphoma (FL) relapsing after an autologous transplant (autoSCT) may be treated with a variety of therapies, including a reduced intensity allogeneic transplant (RICalloSCT). We conducted a retrospective analysis of a large cohort of patients undergoing RICalloSCT for FL in this setting. PATIENTS AND METHODS A total of 183 patients, median age 45 years (range 21-69), had undergone an autoSCT at a median of 30 months before the RICalloSCT. Before the RICalloSCT, they had received a median of four lines (range 3-10) of therapy and 81% of patients had chemosensitive disease and 16% had chemoresistant disease. Grafts were donated from sibling (47%) or unrelated donors (53%). RESULTS With a median follow-up of 59 months, the non-relapse mortality (NRM) was 27% at 2 years. The median remission duration post-autoSCT and RICalloSCT was 14 and 43 months, respectively. The 5-year relapse/progression rate, progression-free survival and overall survival were 16%, 48% and 51%, respectively, and were associated with age and disease status at RICalloSCT. CONCLUSION These data suggest that an RICalloSCT is an effective salvage strategy in patients with FL recurring after a prior autoSCT and might overcome the poor prognostic impact of early relapse after autoSCT.
Collapse
Affiliation(s)
- S P Robinson
- BMT Unit, University Hospital Bristol NHS Foundation Trust, Bristol, UK; Lymphoma Working Party EBMT, Paris, France.
| | | | - H Finel
- Lymphoma Working Party EBMT, Paris, France
| | - H Schouten
- Department of Haematology, University Hospital, Maastricht, The Netherlands
| | - G Ehninger
- Department of Haematology, Universitaetsklinikum, Dresden, Germany
| | - J Maertens
- Department of Haematology, University Hospital Gasthuisberg, Leuven, Belgium
| | - C Crawley
- Department of Haematology, Addenbrookes Hospital, Cambridge, UK
| | - A Rambaldi
- Haematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
| | - N Russell
- Department of Haematology, City Hospital, Nottingham, UK
| | - W Anders
- Department of Haematology, University Hospital, Umea, Sweden
| | - D Blaise
- Department of Haematology, Institut Paoli Calmettes, Marseille
| | - I Yakoub-Agha
- Department of Haematology, Hôpital Claude Huriez, Lille, France
| | - A Ganser
- Department of Haematology, Medical School, Hannover, Germany
| | - L Castagna
- Department of Haematology, Istituto Clinico Humanitas, Milano, Italy
| | - L Volin
- HUH Comprehensive Cancer Center, Stem Cell Transplantation Unit, Helsinki, Finland
| | - J-Y Cahn
- Haematology, Clinique Universitaire d'Hématologie CHU Grenoble UMR 38043, Grenoble Cedex 09, France
| | - S Montoto
- Lymphoma Working Party EBMT, Paris, France; Department of Haematology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK
| | - P Dreger
- Lymphoma Working Party EBMT, Paris, France; Department of Medicine V, University of Heidelberg, Heidelberg, Germany
| |
Collapse
|
15
|
Crocchiolo R, Castagna L, Furst S, Devillier R, Sarina B, Bramanti S, El-Cheikh J, Granata A, Harbi S, Morabito L, Faucher C, Rimondo A, Girardi D, Mohty B, Calmels B, Carlo-Stella C, Chabannon C, Bouabdallah R, Santoro A, Vey N, Weiller PJ, Blaise D. The patient’s CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide. Bone Marrow Transplant 2016; 51:1134-6. [DOI: 10.1038/bmt.2016.69] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
16
|
Rimondo A, Bramanti S, Crocchiolo R, Giordano L, Sarina B, Morabito L, Perotti C, Timofeeva I, Capizzuto R, Santoro A, Castagna L. Bone marrow donor-related variables associated with harvest outcome in HLA-haploidentical transplantation with postinfusion cyclophosphamide. Vox Sang 2016; 111:93-100. [DOI: 10.1111/vox.12385] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2015] [Revised: 12/17/2015] [Accepted: 01/10/2016] [Indexed: 12/18/2022]
Affiliation(s)
- A. Rimondo
- Hematology Unit; Humanitas Cancer Center; Rozzano (Milan) Italy
| | - S. Bramanti
- Hematology Unit; Humanitas Cancer Center; Rozzano (Milan) Italy
| | - R. Crocchiolo
- Hematology Unit; Humanitas Cancer Center; Rozzano (Milan) Italy
| | - L. Giordano
- Biostatistics Unit; Humanitas Cancer Center; Rozzano (Milan) Italy
| | - B. Sarina
- Hematology Unit; Humanitas Cancer Center; Rozzano (Milan) Italy
| | - L. Morabito
- Hematology Unit; Humanitas Cancer Center; Rozzano (Milan) Italy
| | - C. Perotti
- Immunohaematology and Transfusion Service; IRCCS Policlinico San Matteo Foundation; Pavia Italy
| | - I. Timofeeva
- Hematology Unit; Humanitas Cancer Center; Rozzano (Milan) Italy
| | - R. Capizzuto
- Hematology Unit; Humanitas Cancer Center; Rozzano (Milan) Italy
| | - A. Santoro
- Hematology Unit; Humanitas Cancer Center; Rozzano (Milan) Italy
| | - L. Castagna
- Hematology Unit; Humanitas Cancer Center; Rozzano (Milan) Italy
| |
Collapse
|
17
|
Crocchiolo R, Bramanti S, Vai A, Sarina B, Mineri R, Casari E, Tordato F, Mauro E, Timofeeva I, Lugli E, Mavilio D, Carlo-Stella C, Santoro A, Castagna L. Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis. Transpl Infect Dis 2015; 17:242-9. [PMID: 25648539 PMCID: PMC7169814 DOI: 10.1111/tid.12365] [Citation(s) in RCA: 104] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2014] [Revised: 11/24/2014] [Accepted: 01/18/2015] [Indexed: 11/30/2022]
Abstract
BACKGROUND Recently, a platform of T-cell replete haploidentical hematopoietic stem cell transplantation (haplo-HSCT) using post-transplant cyclophosphamide (Cy) has shown high reproducibility and acceptable safety profile. METHOD This prospective cohort analysis allowed us to collect data on infections among 70 consecutive recipients of haplo-HSCT affected by various hematologic malignancies. RESULTS After a median follow-up of 23 months, cumulative incidence of viral infections was 70% (95% confidence interval [CI] 59-81) at 100 days and 77% (95% CI 67-87) at 1 year; 35 of 65 patients at risk had CMV reactivation (54%) and the rate of polyomavirus-virus-associated cystitis was 19% (13/70). Cumulative incidence of bacterial and fungal infections at 1 year were 63% (95% CI 51-75) and 12% (95% CI 4-19), respectively. Of note, only 1 invasive fungal infection occurred beyond 1 year after transplant (day +739). CONCLUSION In conclusion, despite a high rate of viral infections in the early period, present data suggest a satisfactory infectious profile after T-cell replete haplo-HSCT using post-transplant Cy. These results may help clinicians to improve both prophylactic and therapeutic antimicrobial strategies in this emerging haploidentical setting.
Collapse
Affiliation(s)
- R Crocchiolo
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Milan, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Castagna L, Bramanti S, Furst S, Giordano L, Sarina B, Crocchiolo R, El-Cheikh J, Cheikh JE, Granata A, Morabito L, Mauro E, Faucher C, Mohty B, Harbi S, Devillier R, Chabannon C, Carlo-Stella C, Santoro A, Blaise D. Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamide. Bone Marrow Transplant 2015; 51:462-5. [PMID: 26595078 DOI: 10.1038/bmt.2015.289] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- L Castagna
- Department of Hematology, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Italy
| | - S Bramanti
- Department of Hematology, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Italy
| | - S Furst
- Department of Hematology, Transplantation Program Institut Paoli Calmettes, Marseille, France
| | - L Giordano
- Statistic Unit, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Italy
| | - B Sarina
- Department of Hematology, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Italy
| | - R Crocchiolo
- Department of Hematology, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Italy
| | | | - J El Cheikh
- Department of Hematology, Transplantation Program Institut Paoli Calmettes, Marseille, France
| | - A Granata
- Department of Hematology, Transplantation Program Institut Paoli Calmettes, Marseille, France
| | - L Morabito
- Department of Hematology, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Italy
| | - E Mauro
- Department of Hematology, Ospedale Ferrarotto, Catania, Italy
| | - C Faucher
- Department of Hematology, Transplantation Program Institut Paoli Calmettes, Marseille, France
| | - B Mohty
- Department of Hematology, Transplantation Program Institut Paoli Calmettes, Marseille, France
| | - S Harbi
- Department of Hematology, Transplantation Program Institut Paoli Calmettes, Marseille, France
| | - R Devillier
- Department of Hematology, Transplantation Program Institut Paoli Calmettes, Marseille, France
| | - C Chabannon
- Cell Therapy Unit Institut Paoli Calmettes, Marseille, France.,Aix-Marseille Université, Marseille, France.,Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, France
| | - C Carlo-Stella
- Department of Hematology, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Italy
| | - A Santoro
- Department of Hematology, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Italy
| | - D Blaise
- Department of Hematology, Transplantation Program Institut Paoli Calmettes, Marseille, France.,Aix-Marseille Université, Marseille, France.,Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, France
| |
Collapse
|
19
|
Devillier R, Bramanti S, Fürst S, Sarina B, El-Cheikh J, Crocchiolo R, Granata A, Chabannon C, Morabito L, Harbi S, Faucher C, Santoro A, Weiller PJ, Vey N, Carlo-Stella C, Castagna L, Blaise D. T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes. Bone Marrow Transplant 2015; 51:194-8. [PMID: 26551778 DOI: 10.1038/bmt.2015.270] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2015] [Revised: 09/24/2015] [Accepted: 09/29/2015] [Indexed: 11/12/2022]
Abstract
Unmanipulated haploidentical transplantation (Haplo-SCT) using post-transplantation cyclophosphamide (PT-Cy) represents an alternative for patients with high-risk diseases lacking HLA-identical donor. Although it provides low incidences of GVHD, the efficacy of Haplo-SCT is still questioned, especially for patients with myeloid malignancies. Thus, we analyzed 60 consecutive patients with refractory (n=30) or high-risk CR (n=30) AML or myelodysplastic syndromes (MDSs) who underwent PT-Cy Haplo-SCT. The median age was 57 years (22-73 years), hematopoietic cell transplantation comorbidity index was ⩾3 in 38 patients (63%) and Haplo-SCT was the second allogeneic transplantation for 10 patients (17%). Although most of patients received PBSC as graft source (n=48, 80%), we found low incidences of grade 3-4 acute (2%) and severe chronic GVHD (4%). Among patients with high-risk CR diseases, 1-year non-relapse mortality, cumulative incidence of relapse, progression-free and overall survivals were 20%, 32%, 47% and 62%, respectively. In patients with refractory disease, corresponding results were 34%, 35%, 32% and 37%, respectively. We conclude that PT-Cy Haplo-SCT could provide promising anti-leukemic effect even in the setting of very advanced diseases. Thus, it represents a viable alternative for high-risk AML/MDS patients without HLA-identical donor.
Collapse
Affiliation(s)
- R Devillier
- Department of Hematology, Institut Paoli Calmettes, Marseille, France.,Aix-Marseille University, Medicine Faculty, Marseille, France
| | - S Bramanti
- Department of Hematology, Humanitas Cancer Center, Rozzano, Italy
| | - S Fürst
- Department of Hematology, Institut Paoli Calmettes, Marseille, France
| | - B Sarina
- Department of Hematology, Humanitas Cancer Center, Rozzano, Italy
| | - J El-Cheikh
- Department of Hematology, Institut Paoli Calmettes, Marseille, France
| | - R Crocchiolo
- Department of Hematology, Humanitas Cancer Center, Rozzano, Italy
| | - A Granata
- Department of Hematology, Institut Paoli Calmettes, Marseille, France
| | - C Chabannon
- Aix-Marseille University, Medicine Faculty, Marseille, France.,Cell Therapy Facility, Institut Paoli Calmettes, Marseille, France
| | - L Morabito
- Department of Hematology, Humanitas Cancer Center, Rozzano, Italy
| | - S Harbi
- Department of Hematology, Institut Paoli Calmettes, Marseille, France
| | - C Faucher
- Department of Hematology, Institut Paoli Calmettes, Marseille, France
| | - A Santoro
- Department of Hematology, Humanitas Cancer Center, Rozzano, Italy
| | - P-J Weiller
- Department of Hematology, Institut Paoli Calmettes, Marseille, France.,Aix-Marseille University, Medicine Faculty, Marseille, France
| | - N Vey
- Department of Hematology, Institut Paoli Calmettes, Marseille, France.,Aix-Marseille University, Medicine Faculty, Marseille, France
| | - C Carlo-Stella
- Department of Hematology, Humanitas Cancer Center, Rozzano, Italy
| | - L Castagna
- Department of Hematology, Humanitas Cancer Center, Rozzano, Italy
| | - D Blaise
- Department of Hematology, Institut Paoli Calmettes, Marseille, France.,Aix-Marseille University, Medicine Faculty, Marseille, France
| |
Collapse
|
20
|
Garciaz S, Castagna L, Bouabdallah R, Fürst S, Bramanti S, Coso D, Crocchiolo R, El-Cheikh J, Broussais F, Chabannon C, Santoro A, Blaise D. Erratum: Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available. Bone Marrow Transplant 2015; 50:880. [DOI: 10.1038/bmt.2015.79] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
21
|
Blaise D, Saillard C, Fürst S, Faucher C, Prebet T, El Cheikh J, Castagna L, Charbonnier A, Granata A, Rey J, Devillier R, Mohty B, Arnoulet C, Moziconnaci M, Chabannon C, Vey N. 128 SINGLE CENTER EXPERIENCE OF RIC BASED ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN 100 PATIENTS WITH MDS. Leuk Res 2015. [DOI: 10.1016/s0145-2126(15)30129-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
22
|
Garciaz S, Castagna L, Bouabdallah R, Fürst S, Bramanti S, Coso D, Crocchiolo R, El-Cheikh J, Broussais F, Chabannon C, Santoro A, Blaise D. Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available. Bone Marrow Transplant 2015; 50:865-7. [PMID: 25730187 DOI: 10.1038/bmt.2015.22] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Affiliation(s)
- S Garciaz
- Department of Hematology, Institut Paoli Calmettes, Marseille, France
| | - L Castagna
- Department of Hematology, Humanitas Cancer Center, Rozzano, Italy
| | - R Bouabdallah
- Department of Hematology, Institut Paoli Calmettes, Marseille, France
| | - S Fürst
- Department of Hematology, Institut Paoli Calmettes, Marseille, France
| | - S Bramanti
- Department of Hematology, Humanitas Cancer Center, Rozzano, Italy
| | - D Coso
- Department of Hematology, Institut Paoli Calmettes, Marseille, France
| | - R Crocchiolo
- Department of Hematology, Humanitas Cancer Center, Rozzano, Italy
| | - J El-Cheikh
- Department of Hematology, Institut Paoli Calmettes, Marseille, France
| | - F Broussais
- Department of Hematology, Institut Paoli Calmettes, Marseille, France
| | - C Chabannon
- Department of Hematology, Institut Paoli Calmettes, Marseille, France
| | - A Santoro
- Department of Hematology, Humanitas Cancer Center, Rozzano, Italy
| | - D Blaise
- Department of Hematology, Institut Paoli Calmettes, Marseille, France
| |
Collapse
|
23
|
Castagna L, Crocchiolo R, Giordano L, Bramanti S, Carlo-Stella C, Sarina B, Chiti A, Mauro E, Gandolfi S, Todisco E, Balzarotti M, Anastasia A, Magagnoli M, Brusamolino E, Santoro A. High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant. Bone Marrow Transplant 2015; 50:499-504. [PMID: 25621797 DOI: 10.1038/bmt.2014.304] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2014] [Revised: 10/27/2014] [Accepted: 10/31/2014] [Indexed: 11/09/2022]
Abstract
Persistence of disease after salvage therapy among relapsed or refractory Hodgkin lymphoma (HL) patients predicts poor outcome. Here, we report on 41 HL patients with active disease after salvage therapy and who received high-dose melphalan (HD-PAM) and auto-SCT as a bridge to a second autologous or an allogeneic transplantation between 2002 and 2013 at our center. Disease response was based on 18-fluoro-deoxyglucose-positron emission tomography results in all patients. Overall response rate after HD-PAM was 78% and it did not differ among PR or stable/progressive disease patients (P=1.00). Response was associated with better OS: hazard ratio=0.32 (95% confidence interval: 0.13-0.77, P=0.01) irrespective of disease status before HD-PAM. Thirty-three patients (80%) were able to complete the planned treatment, intended as tandem autologous or auto-allo transplant. Hematological and extrahematological toxicity of HD-PAM was manageable, without any treatment-related death. In conclusion, HD-PAM is a valuable therapeutic option in relapsed/refractory HL patients with active disease after salvage therapy, with an impressive 78% overall response rate and 80% rate of proceeding to further transplantation. The present data may be integrated with the growing literature on new drugs in the field of relapsed/refractory HL.
Collapse
Affiliation(s)
- L Castagna
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - R Crocchiolo
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - L Giordano
- Statistic Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - S Bramanti
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - C Carlo-Stella
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - B Sarina
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - A Chiti
- Nuclear Medicine Department, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - E Mauro
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - S Gandolfi
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - E Todisco
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - M Balzarotti
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - A Anastasia
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - M Magagnoli
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - E Brusamolino
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - A Santoro
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| |
Collapse
|
24
|
Magni F, Ceriani D, Castagna L, Ferrari C, Zanella A, Scaravilli V, Colombo SM, Laratta M, Patroniti N. EFFECT OF PEEP ON ESOPHAGEAL CATHETER OPTIMAL CALIBRATION VOLUME AND ESOPHAGEAL PRESSURE MEASUREMENTS. Intensive Care Med Exp 2015. [PMCID: PMC4796973 DOI: 10.1186/2197-425x-3-s1-a1001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
25
|
Castagna L, Bramanti S, Furst S, Giordano L, Crocchiolo R, Sarina B, Mauro E, Morabito L, Bouabdallah R, Coso D, Balzarotti M, Broussais F, El-Cheikh J, Stella CC, Brusamolino E, Blaise D, Santoro A. Erratum: Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas. Bone Marrow Transplant 2014. [DOI: 10.1038/bmt.2014.267] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
26
|
Roberto A, Castagna L, Gandolfi S, Zanon V, Bramanti S, Sarina B, Crocchiolo R, Todisco E, Carlo-Stella C, Tentorio P, Timofeeva I, Santoro A, Della Bella S, Roederer M, Mavilio D, Lugli E. B-cell reconstitution recapitulates B-cell lymphopoiesis following haploidentical BM transplantation and post-transplant CY. Bone Marrow Transplant 2014; 50:317-9. [PMID: 25419693 DOI: 10.1038/bmt.2014.266] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Affiliation(s)
- A Roberto
- Unit of Clinical and Experimental Immunology, Humanitas Clinical and Research Center, Rozzano, Italy
| | - L Castagna
- Hematology and Bone Marrow Transplant Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - S Gandolfi
- Hematology and Bone Marrow Transplant Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - V Zanon
- Unit of Clinical and Experimental Immunology, Humanitas Clinical and Research Center, Rozzano, Italy
| | - S Bramanti
- Hematology and Bone Marrow Transplant Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - B Sarina
- Hematology and Bone Marrow Transplant Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - R Crocchiolo
- Hematology and Bone Marrow Transplant Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - E Todisco
- Hematology and Bone Marrow Transplant Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - C Carlo-Stella
- Hematology and Bone Marrow Transplant Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - P Tentorio
- Unit of Clinical and Experimental Immunology, Humanitas Clinical and Research Center, Rozzano, Italy
| | - I Timofeeva
- Hematology and Bone Marrow Transplant Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - A Santoro
- Hematology and Bone Marrow Transplant Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - S Della Bella
- 1] Unit of Clinical and Experimental Immunology, Humanitas Clinical and Research Center, Rozzano, Italy [2] Department of Medical Biotechnologies and Translational Medicine (BioMeTra), University of Milan, Milan, Italy
| | - M Roederer
- ImmunoTechnology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
| | - D Mavilio
- 1] Unit of Clinical and Experimental Immunology, Humanitas Clinical and Research Center, Rozzano, Italy [2] Department of Medical Biotechnologies and Translational Medicine (BioMeTra), University of Milan, Milan, Italy
| | - E Lugli
- Unit of Clinical and Experimental Immunology, Humanitas Clinical and Research Center, Rozzano, Italy
| |
Collapse
|
27
|
Castagna L, Crocchiolo R, Furst S, El-cheikh J, Esterni B, Granata A, Stoppa A, Boubdallah R, Coso D, Vey N, Charbonnier A, Lemarie C, Faucher C, Chabannon C, Blaise D. Erratum: Reduced-intensity conditioning regimen with in vivo T-cell depletion for patients with haematological malignancies: results using unrelated and sibling donors. Bone Marrow Transplant 2014. [DOI: 10.1038/bmt.2014.191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
28
|
Gaudino A, Tomatis S, Scorsetti M, Navarria P, Lobefalo F, Palumbo V, Reggiori G, Stravato A, Castagna L, Mancosu P. EP-1516: Is delivered multi-isocenter TMI by VMAT consistent with the planned one? In-vivo dosimetry study using GafChromic. Radiother Oncol 2014. [DOI: 10.1016/s0167-8140(15)31634-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
29
|
Mancosu P, Navarria P, Castagna L, Gaudino A, Reggiori G, Palumbo V, Stravato A, Lobefalo F, Scorsetti M, Tomatis S. OC-0398: Managing of field junctions from two CT series in total marrow irradiation with VMAT. Radiother Oncol 2014. [DOI: 10.1016/s0167-8140(15)30503-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
30
|
Mancosu P, Navarria P, Castagna L, Reggiori G, Sarina B, Tomatis S, Alongi F, Fogliata A, Cozzi L, Scorsetti M. Dosimetric Effects of Involuntary Motion for Total Marrow Irradiation With Volumetric Modulated Arc Therapy. Int J Radiat Oncol Biol Phys 2013. [DOI: 10.1016/j.ijrobp.2013.06.1796] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
31
|
Castagna L, Polido W, Soares L, Tinoco E. Tomographic evaluation of iliac crest bone grafting and the use of immediate temporary implants to the atrophic maxilla. Int J Oral Maxillofac Surg 2013; 42:1067-72. [DOI: 10.1016/j.ijom.2013.04.020] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2012] [Revised: 03/08/2013] [Accepted: 04/29/2013] [Indexed: 11/28/2022]
|
32
|
Martínez C, Canals C, Sarina B, Alessandrino EP, Karakasis D, Pulsoni A, Sica S, Trneny M, Snowden JA, Kanfer E, Milpied N, Bosi A, Guidi S, de Souza CA, Willemze R, Arranz R, Jebavy L, Hellmann A, Sibon D, Oneto R, Luan JJ, Dreger P, Castagna L, Sureda A. Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation. Ann Oncol 2013. [PMID: 23712545 DOI: 10.1093/annonc/mdt206.] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
BACKGROUND High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard of care for patients with relapsed Hodgkin's lymphoma (HL). However, there is currently little information on the predictors of outcome for patients whose disease recurs after ASCT. METHODS Five hundred and eleven adult patients with relapsed HL after ASCT from EBMT-GITMO databases were reviewed. RESULTS Treatments administered following ASCT failure included conventional chemotherapy and/or radiotherapy in 294 (64%) patients, second ASCT in 35 (8%), and alloSCT in 133 (29%). After a median follow-up of 49 months, overall survival (OS) was 32% at 5 years. Independent risk factors for OS were early relapse (<6 months) after ASCT, stage IV, bulky disease, poor performance status (PS), and age ≥50 years at relapse. For patients with no risk factors OS at 5 years was 62% compared with 37% and 12% for those having 1 and ≥2 factors, respectively. This score was also predictive for outcome in each group of rescue treatment after ASCT failure. CONCLUSION(S) Early relapse, stage IV, bulky disease, poor PS, and age ≥50 years at ASCT failure are relevant factors for outcome that may help to understand the results of different therapeutic approaches.
Collapse
Affiliation(s)
- C Martínez
- Hematology Department, Institute of Hematology and Oncology, Hospital Clinic, Barcelona, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Martínez C, Canals C, Sarina B, Alessandrino EP, Karakasis D, Pulsoni A, Sica S, Trneny M, Snowden JA, Kanfer E, Milpied N, Bosi A, Guidi S, de Souza CA, Willemze R, Arranz R, Jebavy L, Hellmann A, Sibon D, Oneto R, Luan JJ, Dreger P, Castagna L, Sureda A. Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation. Ann Oncol 2013; 24:2430-4. [PMID: 23712545 DOI: 10.1093/annonc/mdt206] [Citation(s) in RCA: 83] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard of care for patients with relapsed Hodgkin's lymphoma (HL). However, there is currently little information on the predictors of outcome for patients whose disease recurs after ASCT. METHODS Five hundred and eleven adult patients with relapsed HL after ASCT from EBMT-GITMO databases were reviewed. RESULTS Treatments administered following ASCT failure included conventional chemotherapy and/or radiotherapy in 294 (64%) patients, second ASCT in 35 (8%), and alloSCT in 133 (29%). After a median follow-up of 49 months, overall survival (OS) was 32% at 5 years. Independent risk factors for OS were early relapse (<6 months) after ASCT, stage IV, bulky disease, poor performance status (PS), and age ≥50 years at relapse. For patients with no risk factors OS at 5 years was 62% compared with 37% and 12% for those having 1 and ≥2 factors, respectively. This score was also predictive for outcome in each group of rescue treatment after ASCT failure. CONCLUSION(S) Early relapse, stage IV, bulky disease, poor PS, and age ≥50 years at ASCT failure are relevant factors for outcome that may help to understand the results of different therapeutic approaches.
Collapse
Affiliation(s)
- C Martínez
- Hematology Department, Institute of Hematology and Oncology, Hospital Clinic, Barcelona, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Mancosu P, Navarria P, Castagna L, Reggiori G, Sarina B, Tomatis S, Alongi F, Fogliata A, Cozzi L, Scorsetti M. OC-0069: Dosimetric consequences of total marrow irradiation positioning with volumetric modulated arc therapy. Radiother Oncol 2013. [DOI: 10.1016/s0167-8140(15)32375-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
35
|
Abstract
Refractory chronic GVHD (cGVHD) remains a major cause of morbidity after transplantation. Many drugs are used but there is no consensus on the standard of care. We investigated the efficacy of TLI in corticosteroid-refractory cGVHD. We analyzed retrospectively 31 patients receiving one or more TLI session for refractory cGVHD from 2000 to 2007. The main objective was to evaluate the response rate after TLI. Decreased corticosteroid doses and/or discontinued immunosuppressive agents were considered to be surrogate markers of response. All but one patient presented with severe cGVHD at the time of TLI. The median number of previous immunosuppressive treatment lines was 3 (range: 2-4). Fourteen patients (45%) achieved an objective response after TLI and 8 (25%) were cGVHD free at long-term follow-up. In all, 5 (29%) of the 17 nonresponsive patients did not show the features of progressive cGVHD and could decrease the amount of immunosuppressive drugs taken. Response after TLI significantly improved 5-year GVHD-related mortality (14% vs 42%, P=0.038) but not OS (58%vs 64% P=0.27). Regarding the promising response rate in this heavily pretreated population, we reasoned that TLI could be an alternative treatment for corticosteroid-refractory cGVHD.
Collapse
Affiliation(s)
- R Devillier
- Department of Hematology, Transplantation Program, Institut Paoli Calmettes, Marseille, France
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Martino M, Ballestrero A, Zambelli A, Secondino S, Aieta M, Bengala C, Liberati AM, Zamagni C, Musso M, Aglietta M, Schiavo R, Castagna L, Rosti G, Bruno B, Pedrazzoli P. Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry. Bone Marrow Transplant 2012; 48:414-8. [PMID: 22863724 DOI: 10.1038/bmt.2012.149] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The median survival of women with metastatic breast cancer (MBC) is 18-24 months, and fewer than 5% are alive and disease free at 5 years. We report toxicity and survival in a cohort of MBC patients receiving high-dose chemotherapy (HDC) with autologous hematopoietic SCT (AHSCT) in Italy between 1990 and 2005. Data set for survival analysis has been obtained for 415 patients. Clinical parameters including probability of transplant-related mortality (TRM), PFS and OS. With a median follow-up of 27 months (range 0-172), OS and PFS at 5 and 10 years in the whole population were 47/23 and 32/14%, respectively. A total 239 patients are alive with a median follow-up of 33 months (range 2-174). Survival was significantly more pronounced in patients harboring hormone receptor positive tumors (P=0.028), without visceral metastases (P=0.009) and in women with chemosensitive disease (P<0.0001). Sixty eight patients (20.4%) who received HDC in partial response, stable or progressive disease underwent conversion to CR. TRM was 2.5% overall and 1.3% since 2000. Our findings suggest that could be a role for HDC and AHSCT in delaying disease progression and possibly cure a subset of MBC patient harboring chemosensitive tumors.
Collapse
Affiliation(s)
- M Martino
- Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera BMM, Reggio Calabria, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Crocchiolo R, Castagna L, Fürst S, El-Cheikh J, Faucher C, Oudin C, Granata A, Bouabdallah R, Coso D, Chabannon C, Balzarotti M, Santoro A, Blaise D. Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant 2012; 48:249-52. [PMID: 22732704 DOI: 10.1038/bmt.2012.116] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Allo-SCT is used to exploit GVL effect in high-risk relapsed non-Hodgkin's lymphoma (NHL). Here, we retrospectively analyzed 34 high-risk NHL patients who underwent auto-SCT followed closely by reduced-intensity allo-SCT ('tandem auto-allo') from January 2002 to November 2010. The search for an allogeneic donor was started at the beginning of salvage regimen. Median patients' age was 47 (27-68) years; histotypes were: diffuse large B-cell n=5, follicular n=14, transformed follicular n=4, mantle-cell n=5, plasmocytoid lymphoma n=1, anaplastic large T-cell n=2, peripheral T-cell n=3. Donors were HLA-identical siblings (n=29) or 10/10-matched unrelated individuals (n=5). Median interval between auto-SCT and allo-SCT was 77 days (36-197). At a median follow-up of 46 (8-108) months since allo-SCT, 5-year OS is 77% (61-93) and PFS is 68% (51-85). Disease relapse or progression occurred in six patients, 100-day TRM was 0%, 2-year TRM incidence was 6%. In conclusion, tandem transplantation is feasible in high-risk NHL patients having a HLA-identical donor. This approach could represent a suitable therapeutic option for those patients with high-risk NHL potentially benefitting from further therapy after auto-SCT. Donor searches should be started promptly whenever such an approach is chosen.
Collapse
Affiliation(s)
- R Crocchiolo
- Département d'Hématologie, Programme de Transplantation et de Thérapie Cellulaire, Institut Paoli-Calmettes, Marseille, France.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Devillier R, Crocchiolo R, Castagna L, Fürst S, El Cheikh J, Faucher C, Prebet T, Etienne A, Chabannon C, Esterni B, Blaise D. Five Versus 2.5 mg/kg of Anti-Thymocyte-Globulin Dose in Reduced-Intensity-Conditioning Reduces Acute and Chronic Graft-Versus-Host Disease for Patients with Myeloid Malignancies Undergoing Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 2012. [DOI: 10.1016/j.bbmt.2011.12.352] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
39
|
Blaise D, Mohty M, Milpied N, Lecorroller-Soriano AG, Fegueux N, Furst S, Chevallier P, Tabrizi R, Michallet M, Cahn JY, Bay JO, El Cheikh J, Faucher C, Crocchiolo R, Boyer-Chammard A, Castagna L, Boher JM. Allogeneic Stem Cell Transplantation from Matched Related Donor in Patients Over the Age of 55 Years After Reduced Intensity Conditioning Associating Fludarabine-Iv Busulfan and Rabbit-Antithymocyte Globulin: A Prospective Multicenter Phase II Clinical Trial with Socio Economic Evaluation. Biol Blood Marrow Transplant 2012. [DOI: 10.1016/j.bbmt.2011.12.369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
40
|
Crocchiolo R, Castagna L, El-Cheikh J, Helvig A, Fürst S, Faucher C, Vazquez A, Granata A, Coso D, Bouabdallah R, Blaise D. Prior rituximab administration is associated with reduced rate of acute GVHD after in vivo T-cell depleted transplantation in lymphoma patients. Exp Hematol 2011; 39:892-6. [DOI: 10.1016/j.exphem.2011.06.006] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2011] [Revised: 05/25/2011] [Accepted: 06/11/2011] [Indexed: 11/26/2022]
|
41
|
Brugnatelli S, Montagna D, Turin I, Manzoni M, Castagna L, Maestri M, Grecchi I, Santoro A, Pedrazzoli P, Todisco E. 6146 POSTER Preclinical Study of Adoptive Immunotherapy With Natural Killer Cells in Combination With Anti-EGFR Monoclonal Antibodies and Cytokines in Metastatic Colorectal Cancer. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71791-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
42
|
Castagna L, Bramanti S, Sarina B, Todisco E, Ibatici A, Santoro A. ECIL 3-2009 update guidelines for antifungal management. Bone Marrow Transplant 2011; 47:866. [PMID: 21822314 DOI: 10.1038/bmt.2011.154] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
43
|
Mancosu P, Navarria P, Fogliata A, Castagna L, Lobefalo F, Reggiori G, Castiglioni S, Santoro A, Scorsetti M, Cozzi L. 415 poster ANATOMY DRIVEN OPTIMISATION OF GEOMETRICAL PARAMETERS IN MULTI-ARC AND MULTI-ISOCENTRES VOLUMETRIC MODULATED ARC THERAPY TECHNIQUE FOR TOTAL MARROW IRRADIATION. Radiother Oncol 2011. [DOI: 10.1016/s0167-8140(11)70537-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
44
|
Castagna L, Bramanti S, Levis A, Michieli M, Anastasia A, Mazza R, Giordano L, Sarina B, Todisco E, Gregorini A, Santoro A. Pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell support. Ann Oncol 2010; 21:1482-1485. [DOI: 10.1093/annonc/mdp576] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
45
|
Re F, Todisco E, Genovese D, Turin I, Rimassa L, Ibatici A, Castagna L, Santoro A, Montagna D. In vitro preclinical study results for a phase I adoptive immunotherapy trial using cetuximab with allogeneic NK cells in KRAS oncogene-mutated metastatic colorectal cancer patients. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e14057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
46
|
Blaise D, Tabrizi R, Le Corroller A, Michallet M, Bay J, Mohty M, Faucher C, Milpied N, Castagna L, Boyer Chammard A, Boher J. Prospective Comparison of Reduced Intensity (Flu-Bu-ATG) vs. Non-Myeloablative (Flu-TBI) Conditioning For Matched Related allo-SCT: A Clinical and Cost-Effectiveness Multicenter ITAC Study (Mini vs. Micro Trial). Biol Blood Marrow Transplant 2010. [DOI: 10.1016/j.bbmt.2009.12.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
47
|
Farnault L, Esterni B, Faucher C, Furst S, El Cheikh J, Ladaique P, Vey N, Bouabdallah R, Stoppa A, Lemarie C, Calmels B, Castagna L, Mohty M, Chabannon C, Blaise D. The Association Of Fludarabin, Oral Busulfan And Thymoglobulin Prior To Matched Related Allo-SCT Allows For High Long Term Outcome For Both Patients With Myeloid Or Lymphoid Malignancies: Long Term Analysis Of A Homogenous Cohort Of 100 Consecutive Patients. Biol Blood Marrow Transplant 2010. [DOI: 10.1016/j.bbmt.2009.12.387] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
48
|
Castagna L, Fürst S, El-Cheikh J, Faucher C, Vey N, Bouabdallah R, Stoppa AM, Mohty M, Chabannon C, Esterni B, Blaise D. IV Busulfan-Based Reduced Intensity Regimen (RIC) Before Allogeneic Stem Cell Transplantation Is Well Tolerate And Effective In Patients With Hematological Diseases. Biol Blood Marrow Transplant 2010. [DOI: 10.1016/j.bbmt.2009.12.417] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
49
|
Castagna L, Prebet T, Fürst S, El-Cheikh J, Charbonnier A, Faucher C, Mohty M, Chabannon C, Vey N, Blaise D. Tandem Auto-Allo In Acute Myeloid Leukemia (AML) Patients In First Complete Remission (CR). Biol Blood Marrow Transplant 2010. [DOI: 10.1016/j.bbmt.2009.12.360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
50
|
Castagna L, Bramanti S, Levis A, Michieli M, Anastasia A, Mazza R, Sarina B, Todisco E, Giordano L, Santoro A. A phase II randomized study comparing pegfilgrastim (PEG) versus filgrastim (FIL) after high-dose chemotherapy (HDC) and autologous peripheral blood stem cell support (PBSC). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.7038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7038 Background: The aim of this study was to demonstrate the non-inferiority of one fixed dose of PEG compared to daily FIL, in patients (pts) receiving HDC and PBSC. Methods: Criteria for elegibility were: HDC for haematological or solid tumors; at least 3 x10^6/kg CD34+ reinfused; age >18 years; normal cardiac, renal, liver and pulmonary function; signed written informed consent. Pts were randomized to receive on day+1 subcutaneously(sc) PEG (6mg) or 5 mcg/kg/d sc of FIL until ANC >1.0 x 10^9/L. Primary end points were: absolute neutrophil count (ANC) < 0.5 x 10^9/L and the number (no.) of days to achieve an ANC > 0.5 x 10^9/L from day +1. Secondary end points were: no. of days to achieve an ANC > 1.0 x 10^9/L; no. of days with fever > 38 °C; duration of antibiotic therapy; and no. of documented infections. Results: 80 pts were enrolled (40 pts for group). The duration of ANC < 0.5 x 10^9/L, the time to reach an ANC > 0.5 x 10^9/L and the time to reach an ANC > 1.0 x 10^9/L were superimposable in the two groups (mean days 6, 11, 12 respectively ). No. significant differences between FIL versus PEG group were observed in incidence of fever (24 vs 22), no. of documented infections (12 vs 10), no. of days with fever (1.7 vs 0.97 days), duration of antibiotic therapy (5.7 vs 3.5 days). No. differences in terms of extra-hematological toxicities and time to discharge between the two groups (16 vs 14). Time to reach a platelets count > 20 x 10^9/L was significantly shorter in PEG group compared to FIL group (15 vs 11 days, p value 0.05). Conclusions: This study shows that PEG was not inferior to FIL in terms of hematological reconstitution. Additionally PEG significantly shortened duration of thrombocytopenia <20 x 10^9/L. Consequently, PEG could be safely used after PBSC infusion. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- L. Castagna
- Istituto Clinico Humanitas, Rozzano, Italy; Ospedale SSAntonio e Biagio, Alessandria, Italy; Medicina Oncologica Aviano, Pordenone, Italy
| | - S. Bramanti
- Istituto Clinico Humanitas, Rozzano, Italy; Ospedale SSAntonio e Biagio, Alessandria, Italy; Medicina Oncologica Aviano, Pordenone, Italy
| | - A. Levis
- Istituto Clinico Humanitas, Rozzano, Italy; Ospedale SSAntonio e Biagio, Alessandria, Italy; Medicina Oncologica Aviano, Pordenone, Italy
| | - M. Michieli
- Istituto Clinico Humanitas, Rozzano, Italy; Ospedale SSAntonio e Biagio, Alessandria, Italy; Medicina Oncologica Aviano, Pordenone, Italy
| | - A. Anastasia
- Istituto Clinico Humanitas, Rozzano, Italy; Ospedale SSAntonio e Biagio, Alessandria, Italy; Medicina Oncologica Aviano, Pordenone, Italy
| | - R. Mazza
- Istituto Clinico Humanitas, Rozzano, Italy; Ospedale SSAntonio e Biagio, Alessandria, Italy; Medicina Oncologica Aviano, Pordenone, Italy
| | - B. Sarina
- Istituto Clinico Humanitas, Rozzano, Italy; Ospedale SSAntonio e Biagio, Alessandria, Italy; Medicina Oncologica Aviano, Pordenone, Italy
| | - E. Todisco
- Istituto Clinico Humanitas, Rozzano, Italy; Ospedale SSAntonio e Biagio, Alessandria, Italy; Medicina Oncologica Aviano, Pordenone, Italy
| | - L. Giordano
- Istituto Clinico Humanitas, Rozzano, Italy; Ospedale SSAntonio e Biagio, Alessandria, Italy; Medicina Oncologica Aviano, Pordenone, Italy
| | - A. Santoro
- Istituto Clinico Humanitas, Rozzano, Italy; Ospedale SSAntonio e Biagio, Alessandria, Italy; Medicina Oncologica Aviano, Pordenone, Italy
| |
Collapse
|